Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Deimos
San Francisco, California, United Statesdeimostherapeutics.com ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Other
01
Overview
Deimos is an early-stage biotechnology company focused on developing novel therapeutics for neurological and psychiatric disorders. The company leverages a proprietary platform to identify and optimize small molecule candidates that target specific pathways involved in brain function and disease. Deimos aims to address significant unmet medical needs in areas such as depression, anxiety, and neurodegenerative diseases. By combining advanced computational tools with deep biological insights, the company is building a pipeline of innovative drug candidates designed to improve patient outcomes and quality of life.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Deimos.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Deimos.